

Date: May 22, 2023

To,

BSE Limited,
Department of Corporate Services,
Phiroze Jeejeebhoy Towers, Dalal Street,
Mumbai- 400001
BSE Scrip Code: 533014

Dear Sir/Madam,

Sub: Outcome of Board meeting

In continuation of our letter dated 11th May, 2023, we wish to inform you that the Board of Directors of the Company at its meeting held on 22nd May, 2023 has inter alia:

1. Approved the Audited Financial Results (both Standalone & Consolidated) of the Company for the quarter and year ended 31st March, 2023.
2. Recommended Equity Dividend at 6% (ie. 60 paise per share) for the Financial Year 2022-23, subject to approval of shareholders at the ensuing 19th Annual General Meeting (AGM).

Pursuant to Regulation 33 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, copies of the aforesaid audited financial results for the quarter and year ended 31st March, 2023 together with the report of auditors are enclosed herewith. The report of Auditors is with unmodified opinion on the aforesaid Audited Financial Results.

The Board of Directors, at its meeting held today, has also considered and recommended the following, subject to approval of shareholders at the ensuing 19th AGM:


1. Re-appointment of Mr. S. Radhakrishnan (DIN: 00061723) as an Independent Director of the Company for a further period of 5 years w.e.f. 8th August, 2023, based on the recommendation of Nomination & Remuneration Committee.

The meeting of the Board of Directors commenced at 02:40 p.m. (IST) & concluded at 4.38 p.m.

The above intimation be kindly be taken into record.

Thanking You,

Yours Sincerely,
For Sicagen India Limited


(Ankita Jain)
Company Secretary



Sicagen India Ltd.

Registered & Corporate Office:

4th Floor, SPIC House, 88, Mount Road, Guindy, Chennai 600 032 INDIA

Tel: +91 44 4075 4075 | Fax: +91 44 4075 4099 | info@sicagen.com

CIN No.: L74900TN2004PLC053467 | www.sicagen.com